TRANSGENE Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced completion of enrollment in the 120-patient TRAVERSE study. This study is a global randomized phase 2b clinical trial evaluating the efficacy and safety of Pexa-Vec (JX-594/TG6006, pexastimogene devacirepvec) for the treatment of advanced primary liver cancer (hepatocellular carcinoma, HCC) in patients who failed prior therapy with sorafenib (Nexavar®). Pexa-Vec is an investigational oncolytic immunotherapy designed to 1) rapidly de-bulk tumors via tumor cell lysis, 2) induce a durable immune response against tumors, and 3) selectively target tumor vasculature resulting in a rapid reduction in tumor blood flow.

Help employers find you! Check out all the jobs and post your resume.

Back to news